Ghent University Academic Bibliography

Your filters: cql: author="Deeren, Dries" or (type any "bookEditor issueEditor" and editor="Deeren, Dries")

Add to list
- Journal Article
- A1
- open access
Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

Philippe Decruyenaere (UGent) , Edoardo Giuili, Kimberly Verniers (UGent) , Jasper Anckaert (UGent) , Katrien De Grove (UGent) , Malaïka Van der Linden (UGent) , Dries Deeren, Jo Van Dorpe (UGent) , Fritz Offner (UGent) and Jo Vandesompele (UGent)

(2023) FRONTIERS IN ONCOLOGY. 13.
Add to list
Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT) : a prospective study from the Belgian Hematology Society (BHS)

Xavier Poire, Carlos Graux, Aurelie Ory, Julie Herman, Frederic Baron, Helene Schoemans, Philippe Lewalle, Ann De Becker, Dries Deeren, Zwi Berneman, et al.

(2022) BONE MARROW TRANSPLANTATION. 57(1). p.116-118
Add to list
- Journal Article
- A1
- open access
Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis : a standardized approach with underappreciated potential

Lennart Raman, Malaïka Van der Linden (UGent) , Ciel De Vriendt (UGent) , Bliede Van den Broeck (UGent) , Kristoff Muylle, Dries Deeren, Franceska Dedeurwaerdere, Sofie Verbeke (UGent) , Amélie Dendooven (UGent) , Katrien De Grove (UGent) , et al.

(2022) HAEMATOLOGICA. 107(1). p.211-220
Add to list
- Journal Article
- A1
- open access
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL : the HOVON-100 trial

Anita W. Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J. Biemond, Arjen A. van de Loosdrecht, Lotte E. van der Wagen, Mar Bellido, Michel van Gelder, Walter J. F. M. van der Velden, Dominik Selleslag, et al.

(2022) BLOOD ADVANCES. 6(4). p.1115-1125
Add to list
Use of chimerism analysis after allogeneic stem cell transplantation : Belgian guidelines and review of the current literature

Anke Delie (UGent) , Anke Verlinden, Karolien Beel, Dries Deeren, Dominiek Mazure (UGent) , Frederic Baron, Dimitri Breems, Ann De Becker, Carlos Graux, Philippe Lewalle, et al.

(2021) ACTA CLINICA BELGICA. 76(6). p.500-508
Add to list
- Journal Article
- A1
- open access
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry

Timothy Devos, Violaine Havelange, Koen Theunissen, Stef Meers, Fleur Samantha Benghiat, Alain Gadisseur, Gaetan Vanstraelen, Helene Vellemans, Benjamin Bailly, Nikki Granacher, et al.

(2021) ANNALS OF HEMATOLOGY. 100(7). p.1723-1732
Add to list
Using the World Apheresis Association registry helps to improve the treatment quality of therapeutic apheresis

Bernd Stegmayr, Elizabeth Newman, Volker Witt, Kurt Derfler, Gerda Leitner, Sunny Eloot (UGent) , Annemieke Dhondt (UGent) , Dries Deeren, Jan Ptak, Milan Blaha, et al.

(2021) TRANSFUSION MEDICINE AND HEMOTHERAPY. 48(4). p.234-239
Add to list
- Journal Article
- A1
- open access
Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with AML and high risk MDS

Jeroen Janssen, Bob Lowenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Peter von Dem Borne, Dimitri Breems, Rolf Brouwer, Yves Chalandon, Dries Deeren, et al.

(2021) CANCERS. 13(4).
Add to list
- Journal Article
- A1
- open access
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : the HOVON-SAKK-132 trial

Bob Lowenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, et al.

(2021) BLOOD ADVANCES. 5(4). p.1110-1121
Add to list
- Conference Paper
- C3
Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring: a standardized approach with underappreciated potential

Malaïka Van der Linden (UGent) , Lennart Raman, Ciel De Vriendt (UGent) , Bliede Van den Broeck (UGent) , Kristoff Muylle, Dries Deeren, Kathleen Claes (UGent) , Björn Menten (UGent) , Fritz Offner (UGent) and Jo Van Dorpe (UGent)

(2020) 35th General Annual Meeting of the Belgian Hematology Society 2020, Abstracts.

Academic Bibliography

Exploring the cell-free total RNA transcriptome in diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma patients as biomarker source in blood plasma liquid biopsies

Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT) : a prospective study from the Belgian Hematology Society (BHS)

Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis : a standardized approach with underappreciated potential

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL : the HOVON-100 trial

Use of chimerism analysis after allogeneic stem cell transplantation : Belgian guidelines and review of the current literature

Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry

Using the World Apheresis Association registry helps to improve the treatment quality of therapeutic apheresis

Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with AML and high risk MDS

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : the HOVON-SAKK-132 trial

Shallow whole-genome sequencing of cell-free DNA for B-cell lymphoma diagnosis and disease monitoring: a standardized approach with underappreciated potential

Contents

Support

Contact